<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E83273DC-36F6-44ED-AAE6-5BE8951F4719"><gtr:id>E83273DC-36F6-44ED-AAE6-5BE8951F4719</gtr:id><gtr:firstName>Kate</gtr:firstName><gtr:surname>Bishop</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117592729"><gtr:id>BD4BD6A1-22FE-4D75-83D5-5CF7990B163B</gtr:id><gtr:title>Infection and replication of retroviruses</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117592729</gtr:grantReference><gtr:abstractText>Retroviruses cause severe diseases including immunodeficiency and cancer. Over 33 million people are currently living with HIV/AIDS, and recently, a novel retrovirus called XMRV has been linked to human prostate cancer. Like all viruses, retroviruses can only replicate inside host cells. Some host cell factors are required for replication whilst others inhibit replication. Identifying and understanding the interactions between viral and host cell factors are key to developing new treatments to combat disease. A greater understanding of retroviral replication might also be of use in research to advance gene therapy for other diseases, by improving the efficiency of retroviral-based vectors used for gene delivery. Furthermore, such knowledge could help to develop better animal models for HIV/AIDS.||Research in my laboratory aims to advance our understanding of retroviral replication. We focus on two areas: Firstly, we study mutant viruses that are unable to complete the early stages of infection to determine why they cannot replicate and to try to identify novel cellular proteins that are involved in these steps. Secondly, we are investigating the link between XMRV and prostate cancer by determining whether patients make antibody responses to this virus. We will then explore the prevalence of this virus in the population.</gtr:abstractText><gtr:technicalSummary>Retroviruses cause severe diseases, including immunodeficiency and cancer. Without a vaccine, and given the economic, compliance and viral resistance concerns that accompany the current combination therapies, the need to improve and expand anti-retroviral treatments is of utmost importance. Innovative therapeutics will hopefully arise from a better understanding of how retroviruses reproduce in the cell, how they interact with host cell factors and how they subvert the host innate and adaptive immune systems.||The research in my laboratory is divided into two projects. The first is to investigate early post-entry retroviral replication processes, initially by studying a protein from the model retrovirus, murine leukaemia virus (MLV), called p12. p12 is formed when the Gag poly-protein is cleaved into individual proteins during viral maturation and it is essential for MLV replication. Mutagenesis studies have implicated the p12 protein in the trafficking of preintegration complexes (PICs) through the host cell cytoplasm and/or nuclear entry, as viruses with specific mutations in p12 are unable to accrue their nascent cDNA in the cell nucleus. This is a particularly poorly understood stage of the retroviral lifecycle. The key aim of this project is to understand the function of p12 and how it contributes to early post-entry events during retroviral infection. Using a variety of virological assays we are assessing whether p12 recruits a cellular factor to the PIC that is required for replication, or if it blocks a cellular inhibitor of infection. We hope to identify novel cellular proteins involved in early post-entry processes by analysing the biochemical interactions of p12 including the protein complexes of TAP-tagged p12. In addition, we wish to use microscopy to observe the location of p12 and any aberrant PIC trafficking patterns arising from p12 mutations.||The second project in my laboratory involves a novel retrovirus similar to MLV called xenotropic MLV-related virus (XMRV). This virus has recently been isolated from patients with familial prostate cancer. These patients expressed a defective R462Q variant of RNaseL, a protein involved in the antiviral response triggered by interferon. We are interested in examining the links between XMRV, cancer and RNaseL. We are taking a serological approach to analyse XMRV infection in prostate cancer patients. We are setting up a neutralization assay and other antibody detection systems to test patients blood samples for evidence of a response to the virus. If this approach is successful, we intend to broaden the study to investigate how widespread the virus is in the general population and the impact this has on public health. We will also investigate the effects of RNaseH and additional members of this innate immune pathway on XMRV and other retroviral infections.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2510902</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>749611</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>B60D8D08-4C24-4543-8EE4-A82F499F1789</gtr:id><gtr:outcomeId>eZqwNLhSEa50</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D2810872-751D-4DB3-95E4-8FA3F6F089F7</gtr:id><gtr:title>Phospho-dependent Regulation of SAMHD1 Oligomerisation Couples Catalysis and Restriction.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a7774931da296e9244084fe229ea4b0"><gtr:id>9a7774931da296e9244084fe229ea4b0</gtr:id><gtr:otherNames>Arnold LH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56c48fdf3437f6.59692625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0141445A-F41E-4266-B455-35BFB881E17C</gtr:id><gtr:title>Molecular determinants for recognition of divergent SAMHD1 proteins by the lentiviral accessory protein Vpx.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0e91978b81c011b0d7d6bb8b4f367c1"><gtr:id>b0e91978b81c011b0d7d6bb8b4f367c1</gtr:id><gtr:otherNames>Schwefel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>56c4905b16bab6.01285966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94F3B126-F76A-43E8-AACF-B863257D6B94</gtr:id><gtr:title>Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1967f1ef6807f4bedadc0b6799a69e9a"><gtr:id>1967f1ef6807f4bedadc0b6799a69e9a</gtr:id><gtr:otherNames>Groom HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>YDxRCRy3bPu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7AA2E98-91BC-4375-B919-B458E4A5B5F5</gtr:id><gtr:title>Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1967f1ef6807f4bedadc0b6799a69e9a"><gtr:id>1967f1ef6807f4bedadc0b6799a69e9a</gtr:id><gtr:otherNames>Groom HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>ZNu7Ru28G9e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>236C24D5-B609-463E-B6D8-127AE73B82F1</gtr:id><gtr:title>Chronic fatigue syndrome, the immune system and viral infection.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7e1be5e122672a620f562826993992"><gtr:id>5e7e1be5e122672a620f562826993992</gtr:id><gtr:otherNames>Bansal AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>pm_14532_22_21756995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F428420A-41A8-4BBA-86B8-C65AACB9984A</gtr:id><gtr:title>No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1967f1ef6807f4bedadc0b6799a69e9a"><gtr:id>1967f1ef6807f4bedadc0b6799a69e9a</gtr:id><gtr:otherNames>Groom HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14532_22_22470540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CAF5B75-C568-432F-B5F7-1F2FF5C7D1C2</gtr:id><gtr:title>The gammaretroviral p12 protein has multiple domains that function during the early stages of replication.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2501d915e437cca39e80b8568e34727"><gtr:id>b2501d915e437cca39e80b8568e34727</gtr:id><gtr:otherNames>Wight DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_14532_22_23035841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0F61408-665A-4513-9F4A-3536C2A3D7B6</gtr:id><gtr:title>Structural basis of lentiviral subversion of a cellular protein degradation pathway.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0e91978b81c011b0d7d6bb8b4f367c1"><gtr:id>b0e91978b81c011b0d7d6bb8b4f367c1</gtr:id><gtr:otherNames>Schwefel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_540e182e182bd4c9c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>732B26D9-1612-4B26-81CC-B3AB548D28B5</gtr:id><gtr:title>The tale of xenotropic murine leukemia virus-related virus.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1967f1ef6807f4bedadc0b6799a69e9a"><gtr:id>1967f1ef6807f4bedadc0b6799a69e9a</gtr:id><gtr:otherNames>Groom HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_14532_22_22357751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31278953-7C10-429B-BC06-727C7EFD3ADB</gtr:id><gtr:title>The N-terminus of murine leukaemia virus p12 protein is required for mature core stability.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2501d915e437cca39e80b8568e34727"><gtr:id>b2501d915e437cca39e80b8568e34727</gtr:id><gtr:otherNames>Wight DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5457a8441f25a4.59986775</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U117592729</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>